- Home
- BRLT vs CVM Comparison
BRLT vs CVM Comparison
Compare BRLT & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRLT | CVM |
|---|---|---|
| Founded | 2005 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.6M | 43.3M |
| IPO Year | 2021 | 1987 |
Fundamental Metrics
Financial Performance| Metric | BRLT | CVM |
|---|---|---|
| Price | $1.56 | $5.29 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $1.80 | N/A |
| AVG Volume (30 Days) | 69.1K | ★ 80.6K |
| Earning Date | 03-11-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $432,597,000.00 | N/A |
| Revenue This Year | $5.92 | N/A |
| Revenue Next Year | $4.06 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.31 | N/A |
| 52 Week Low | $1.25 | $1.98 |
| 52 Week High | $3.10 | $20.41 |
Technical Indicators
Market Signals| Indicator | BRLT | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 37.38 | 44.66 |
| Support Level | $1.53 | $4.90 |
| Resistance Level | $1.66 | $6.75 |
| Average True Range (ATR) | 0.08 | 0.64 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 11.11 | 21.62 |
Price Performance
Historical ComparisonAbout BRLT Brilliant Earth Group Inc.
Brilliant Earth Group Inc is a digitally native omnichannel jewelry company. The company designs, procures and sells ethically-sourced diamonds, gemstones and jewelry online and through showrooms. The sales of the company consist of revenue from diamond, gemstone, and jewelry retail sales. The company sells its products in the U.S. and other international countries, of which a majority of revenue is derived from the U.S.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.